X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs AJANTA PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD AJANTA PHARMA ORCHID PHARMA LTD/
AJANTA PHARMA
 
P/E (TTM) x -0.5 25.4 - View Chart
P/BV x 0.4 10.5 3.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ORCHID PHARMA LTD   AJANTA PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
AJANTA PHARMA
Mar-16
ORCHID PHARMA LTD/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,720 11.3%   
Low Rs351,103 3.2%   
Sales per share (Unadj.) Rs276.5194.6 142.1%  
Earnings per share (Unadj.) Rs-79.245.2 -175.2%  
Cash flow per share (Unadj.) Rs-43.550.3 -86.4%  
Dividends per share (Unadj.) Rs08.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs53.9132.0 40.9%  
Shares outstanding (eoy) m70.4588.77 79.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.47.3 5.7%   
Avg P/E ratio x-1.431.2 -4.6%  
P/CF ratio (eoy) x-2.628.1 -9.4%  
Price / Book Value ratio x2.110.7 19.9%  
Dividend payout %017.7 0.0%   
Avg Mkt Cap Rs m8,067125,299 6.4%   
No. of employees `0002.8NA-   
Total wages/salary Rs m2,5272,570 98.3%   
Avg. sales/employee Rs Th6,956.1NM-  
Avg. wages/employee Rs Th902.5NM-  
Avg. net profit/employee Rs Th-1,993.0NM-  
INCOME DATA
Net Sales Rs m19,47717,275 112.7%  
Other income Rs m407166 244.9%   
Total revenues Rs m19,88417,442 114.0%   
Gross profit Rs m1,1035,807 19.0%  
Depreciation Rs m2,519451 559.1%   
Interest Rs m5,22749 10,688.8%   
Profit before tax Rs m-6,2365,474 -113.9%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,460 -8.6%   
Profit after tax Rs m-5,5804,014 -139.0%  
Gross profit margin %5.733.6 16.8%  
Effective tax rate %2.026.7 7.5%   
Net profit margin %-28.723.2 -123.3%  
BALANCE SHEET DATA
Current assets Rs m11,0147,639 144.2%   
Current liabilities Rs m32,0602,715 1,181.0%   
Net working cap to sales %-108.128.5 -379.1%  
Current ratio x0.32.8 12.2%  
Inventory Days Days9543 219.5%  
Debtors Days Days3479 42.7%  
Net fixed assets Rs m29,4406,914 425.8%   
Share capital Rs m705177 398.2%   
"Free" reserves Rs m2,04311,442 17.9%   
Net worth Rs m3,80011,721 32.4%   
Long term debt Rs m9,018149 6,064.5%   
Total assets Rs m46,51014,814 314.0%  
Interest coverage x-0.2112.9 -0.2%   
Debt to equity ratio x2.40 18,705.6%  
Sales to assets ratio x0.41.2 35.9%   
Return on assets %-0.827.4 -2.8%  
Return on equity %-146.934.2 -428.8%  
Return on capital %-3.746.5 -8.0%  
Exports to sales %37.955.1 68.7%   
Imports to sales %22.66.0 376.6%   
Exports (fob) Rs m7,3789,527 77.4%   
Imports (cif) Rs m4,4061,038 424.6%   
Fx inflow Rs m7,51310,422 72.1%   
Fx outflow Rs m5,6491,678 336.6%   
Net fx Rs m1,8658,744 21.3%   
CASH FLOW
From Operations Rs m1,6823,264 51.5%  
From Investments Rs m-9,860-2,093 471.1%  
From Financial Activity Rs m6,644-1,186 -560.3%  
Net Cashflow Rs m-1,535-15 10,371.6%  

Share Holding

Indian Promoters % 32.3 73.8 43.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 1.6 296.8%  
FIIs % 3.3 7.6 43.4%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 17.0 325.3%  
Shareholders   84,811 20,968 404.5%  
Pledged promoter(s) holding % 54.9 4.4 1,251.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   SUVEN LIFE  SHASUN PHARMA  SANOFI INDIA  TTK HEALTHCARE  SUN PHARMA  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS